CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath - June 21, 2023

CorMedix Inc. has announced that the US Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application for DefenCath, a catheter lock solution that is being developed to reduce catheter-related bloodstream infections in patients with kidney failure who are receiving chronic hemodialysis via a central venous catheter. The FDA considers the resubmission as a complete,..